Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 20 January 2012 | By Alexander Gaffney, RAC
The European Medicines Agency (EMA) today called on EU national regulatory authorities, including France, UK and Italy, to withdraw their respective Marketing Authorizations (MA) for oral meprobamate-containing medications. The medication has been associated with severe side effects including overdose, coma and death.
Meprobamate is a prescription sedative medicine used to treat anxiety, alcohol withdrawal, migraine attacks, disgestive disorders, muscle tensions, muscle cramps and insomnia. It is currently available in France, the Netherlands, Finaland, Hungary, Italy, Romania, UK, Iceland and Norway.
The French regulatory authority, Afssaps, alerted EMA in July of 2011 that they intended to suspend the MA for meprobamate because of the long list of side effects, including confusion, loss of consciousness, addiction, severe withdrawal symptoms, overdose, coma and death.
After reviewing the medication, EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that "the benefits of meprobamate do not outweigh its risks", and recommended that all national authorities remove meprobamate from the market gradually over the next 15 months. CHMP further recommended that doctors stop prescribing the medication due to the unfavorable risk-benefit assessment.
Severe withdrawal symptoms are associated with stopping oral meprobamte-containing medications too quickly, and the CHMP found the difference between an adequate treatment dose and an overdose to be minor.
EMA's notice said that the European Commission will issue a decision on their opinion "in due course."
Tags: Withdraw, Sedative, Meprobamate, Latest News, CHMP, EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.